Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
Piedmont Hematology-Oncology Associates
mi
from
Winston-Salem, NC
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
Piedmont Hematology-Oncology Associates
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
Mid Ohio Oncology Hematology, Inc.
mi
from
Columbus, OH
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
Mid Ohio Oncology Hematology, Inc.
mi
from
Columbus, OH
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
Providence Portland Medical Center
mi
from
Portland, OR
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
Regional Hemetology Oncology, Pc
mi
from
Langhorne, PA
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
Regional Hemetology Oncology, Pc
mi
from
Langhorne, PA
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
Upmc Cancer Pavilion
mi
from
Pittsburgh, PA
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
Upmc Cancer Pavilion
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
VA Pittsburgh Healthcare System
mi
from
Pittsburgh, PA
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
VA Pittsburgh Healthcare System
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
Miriam Hospital
mi
from
Providence, RI
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
Miriam Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
Cancer Centers of the Carolinas
mi
from
Greenville, SC
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
Cancer Centers of the Carolinas
mi
from
Greenville, SC
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
Boston Baskin Cancer Foundation
mi
from
Memphis, TN
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
Boston Baskin Cancer Foundation
mi
from
Memphis, TN
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
Providence Regional Cancer System
mi
from
Lacey, WA
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
Providence Regional Cancer System
mi
from
Lacey, WA
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
Univ of Washington
mi
from
Seattle, WA
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/13/2015
Local Institution
mi
from
Caba,
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/13/2015
Local Institution
mi
from
Caba,
Click here to add this to my saved trials
Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer
Measuring the Effect of Additional Tumor Cavity Margins Excision at the Time of Breast Conserving Surgery for Stage 0, I, II, and III Breast Cancer Patients on Re-excision Rate, Cosmetic Results and Total Costs
Status: Enrolling
Updated:  8/13/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer
Measuring the Effect of Additional Tumor Cavity Margins Excision at the Time of Breast Conserving Surgery for Stage 0, I, II, and III Breast Cancer Patients on Re-excision Rate, Cosmetic Results and Total Costs
Status: Enrolling
Updated: 8/13/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Maintenance Dovitinib for Colorectal and Pancreas Cancer
A Pilot Study of Dovitinib as Maintenance and Adjuvant Therapy in Patients With Colorectal and Pancreas Cancers
Status: Enrolling
Updated:  8/13/2015
Georgetown University Lombardi Cancer Center
mi
from
Washington,
Maintenance Dovitinib for Colorectal and Pancreas Cancer
A Pilot Study of Dovitinib as Maintenance and Adjuvant Therapy in Patients With Colorectal and Pancreas Cancers
Status: Enrolling
Updated: 8/13/2015
Georgetown University Lombardi Cancer Center
mi
from
Washington,
Click here to add this to my saved trials
Pelvic IMRT With Tomotherapy: A Phase I Feasibility Study in Post-Hysterectomy Cervical Cancer Patients
Pelvic IMRT With Tomotherapy: A Phase I Feasibility Study in Post-Hysterectomy Cervical Cancer Patients
Status: Enrolling
Updated:  8/14/2015
Washington University School of Medicine
mi
from
St. Louis, MO
Pelvic IMRT With Tomotherapy: A Phase I Feasibility Study in Post-Hysterectomy Cervical Cancer Patients
Pelvic IMRT With Tomotherapy: A Phase I Feasibility Study in Post-Hysterectomy Cervical Cancer Patients
Status: Enrolling
Updated: 8/14/2015
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma
Velcade (Bortezomib) and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/14/2015
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma
Velcade (Bortezomib) and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/14/2015
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma
Velcade (Bortezomib) and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/14/2015
The Cancer Center at Presbyterian
mi
from
Albuquerque, NM
Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma
Velcade (Bortezomib) and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/14/2015
The Cancer Center at Presbyterian
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma
Velcade (Bortezomib) and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  8/14/2015
Memorial Medical Center- Cancer Center
mi
from
Las Cruces, NM
Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma
Velcade (Bortezomib) and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 8/14/2015
Memorial Medical Center- Cancer Center
mi
from
Las Cruces, NM
Click here to add this to my saved trials
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
A Phase 1b, Multi-Center, Open-Label Study of the mTOR Kinase Inhibitor CC-223 in Combination With Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  8/14/2015
Cedars Sinai
mi
from
Los Angeles, CA
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
A Phase 1b, Multi-Center, Open-Label Study of the mTOR Kinase Inhibitor CC-223 in Combination With Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 8/14/2015
Cedars Sinai
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
A Phase 1b, Multi-Center, Open-Label Study of the mTOR Kinase Inhibitor CC-223 in Combination With Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  8/14/2015
ITOR Cancer Center of North Carolina
mi
from
Greenville, SC
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
A Phase 1b, Multi-Center, Open-Label Study of the mTOR Kinase Inhibitor CC-223 in Combination With Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 8/14/2015
ITOR Cancer Center of North Carolina
mi
from
Greenville, SC
Click here to add this to my saved trials
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
A Phase 1b, Multi-Center, Open-Label Study of the mTOR Kinase Inhibitor CC-223 in Combination With Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  8/14/2015
Mary Crowley Cancer Research Center
mi
from
Dallas, TX
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
A Phase 1b, Multi-Center, Open-Label Study of the mTOR Kinase Inhibitor CC-223 in Combination With Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 8/14/2015
Mary Crowley Cancer Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
A Phase 1b, Multi-Center, Open-Label Study of the mTOR Kinase Inhibitor CC-223 in Combination With Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  8/14/2015
University of Texas - MD Anderson
mi
from
Houston, TX
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
A Phase 1b, Multi-Center, Open-Label Study of the mTOR Kinase Inhibitor CC-223 in Combination With Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 8/14/2015
University of Texas - MD Anderson
mi
from
Houston, TX
Click here to add this to my saved trials
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
A Phase 1b, Multi-Center, Open-Label Study of the mTOR Kinase Inhibitor CC-223 in Combination With Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  8/14/2015
Vanderbilt University Medical Center
mi
from
Nashville, TN
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
A Phase 1b, Multi-Center, Open-Label Study of the mTOR Kinase Inhibitor CC-223 in Combination With Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 8/14/2015
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
A Phase 1b, Multi-Center, Open-Label Study of the mTOR Kinase Inhibitor CC-223 in Combination With Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  8/14/2015
University of California at San Francisco
mi
from
San Francisco, CA
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
A Phase 1b, Multi-Center, Open-Label Study of the mTOR Kinase Inhibitor CC-223 in Combination With Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 8/14/2015
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
A Phase 1b, Multi-Center, Open-Label Study of the mTOR Kinase Inhibitor CC-223 in Combination With Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  8/14/2015
NYU Cancer Institute
mi
from
New York, NY
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
A Phase 1b, Multi-Center, Open-Label Study of the mTOR Kinase Inhibitor CC-223 in Combination With Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 8/14/2015
NYU Cancer Institute
mi
from
New York, NY
Click here to add this to my saved trials
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
A Phase 1b, Multi-Center, Open-Label Study of the mTOR Kinase Inhibitor CC-223 in Combination With Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  8/14/2015
Hospital Universitari Vall d'Hebron
mi
from
Barcelona,
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
A Phase 1b, Multi-Center, Open-Label Study of the mTOR Kinase Inhibitor CC-223 in Combination With Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 8/14/2015
Hospital Universitari Vall d'Hebron
mi
from
Barcelona,
Click here to add this to my saved trials
Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
A Phase II Randomized Open Label Study of Sipuleucel-T vs. Sipuleucel-T and Tasquinimod in Patients With Metastatic Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  8/14/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
A Phase II Randomized Open Label Study of Sipuleucel-T vs. Sipuleucel-T and Tasquinimod in Patients With Metastatic Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 8/14/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Corona, CA
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Corona, CA
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Fountain Valley, CA
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Fullerton, CA
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Fullerton, CA
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Glendale, CA
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Glendale, CA
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
La Jolla, CA
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Riverside, CA
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Riverside, CA
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Washington,
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Orange City, FL
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Orange City, FL
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Quincy, IL
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Quincy, IL
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Indianapolis, IN
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Louisville, KY
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Boston, MA
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Lake Success, NY
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Lake Success, NY
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Durham, NC
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Cleveland, OH
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Sylvania, OH
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Sylvania, OH
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
West Reading, PA
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
West Reading, PA
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Charleston, SC
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Falls Church, VA
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Falls Church, VA
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
mi
from
Prairiewood,
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
mi
from
Prairiewood,
Click here to add this to my saved trials
A Study of the Drug-Drug Interaction of RO5503781 and Posaconazole, the Relative Bioavailability of New Formulations of RO5503781 and the Food-Effect on the Pharmacokinetics of RO5503781 in Patients With Solid Tumors
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Scottsdale, AZ
A Study of the Drug-Drug Interaction of RO5503781 and Posaconazole, the Relative Bioavailability of New Formulations of RO5503781 and the Food-Effect on the Pharmacokinetics of RO5503781 in Patients With Solid Tumors
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study of the Drug-Drug Interaction of RO5503781 and Posaconazole, the Relative Bioavailability of New Formulations of RO5503781 and the Food-Effect on the Pharmacokinetics of RO5503781 in Patients With Solid Tumors
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Dallas, TX
A Study of the Drug-Drug Interaction of RO5503781 and Posaconazole, the Relative Bioavailability of New Formulations of RO5503781 and the Food-Effect on the Pharmacokinetics of RO5503781 in Patients With Solid Tumors
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of the Drug-Drug Interaction of RO5503781 and Posaconazole, the Relative Bioavailability of New Formulations of RO5503781 and the Food-Effect on the Pharmacokinetics of RO5503781 in Patients With Solid Tumors
Status: Enrolling
Updated:  8/17/2015
mi
from
Toronto,
A Study of the Drug-Drug Interaction of RO5503781 and Posaconazole, the Relative Bioavailability of New Formulations of RO5503781 and the Food-Effect on the Pharmacokinetics of RO5503781 in Patients With Solid Tumors
Status: Enrolling
Updated: 8/17/2015
mi
from
Toronto,
Click here to add this to my saved trials